Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Court sided with Pfizer again for Lyrica
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Feb 11, 2014 16:51:04
Seoul Central Court sided with Pfizer Korea, ruling on February 10 that Samjin should not market its generic version of Lyrica for the treatment of pain.

The court said that Samjin should not manufacture and market its generic version as a pain treatment until August 14, 2017.

Lee Dong Su, President of Pfizer Korea, said, “The court dismissed two cases of generic drug makers to invalidate the patent on the use of Lyrica. The latest ruling confirmed again that the innovativeness deserves patent protection.”

Pfizer Korea also won the similar case of Lyrica against CJ in May 2013.
Reply 0
Name Password
Popular News
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com